New Risk • Apr 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩11b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩11b free cash flow). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (59% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩3.4b revenue, or US$2.3m). Market cap is less than US$100m (₩80.2b market cap, or US$53.2m). Announcement • Mar 13
SyntekaBio, Inc., Annual General Meeting, Mar 27, 2026 SyntekaBio, Inc., Annual General Meeting, Mar 27, 2026, at 11:00 Tokyo Standard Time. Location: seminar room, 18, gukjegwahak 17-ro, yuseong-gu, daejeon South Korea New Risk • Jan 07
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 59% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (59% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩1.8b revenue, or US$1.2m). Market cap is less than US$100m (₩89.8b market cap, or US$62.0m). Announcement • Dec 19
SyntekaBio, Inc. has completed a Follow-on Equity Offering in the amount of KRW 24.3 billion. SyntekaBio, Inc. has completed a Follow-on Equity Offering in the amount of KRW 24.3 billion.
Security Name: Common stock
Security Type: Common Stock
Securities Offered: 8,898,184
Price\Range: KRW 2700
Discount Per Security: KRW 48.6
Security Name: Common stock
Security Type: Common Stock
Securities Offered: 101,816
Price\Range: KRW 2700
Transaction Features: Rights Offering New Risk • Nov 29
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩11b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩11b free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩1.8b revenue, or US$1.2m). Market cap is less than US$100m (₩70.8b market cap, or US$48.2m). New Risk • Oct 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.7% per year over the past 5 years. Revenue is less than US$1m (₩1.3b revenue, or US$942k). Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Market cap is less than US$100m (₩63.0b market cap, or US$44.7m). Announcement • Sep 04
SyntekaBio, Inc. announced that it expects to receive KRW 10 billion in funding from Sangsangin Savings Bank, Saejong Ind Co., Ltd. SyntekaBio, Inc. announced a private placement to issue 2% Series 4 Unregistered Interest Unsecured Private Convertible Bonds due September 12, 2028 for gross proceeds of KRW 10,000,000,000 on September 3, 2025. The transaction will include participation from new investors Sangsangin Savings Bank for KRW 9.000,000,000 and Saejong Ind Co., Ltd. for KRW 1,000,000,000. The transaction has been approved by shareholders, expected to close on September 12, 2025, bears 2% coupon rate, 6% maturity rate and matures on September 12, 2028, 100% convertible into 1,766,784 shares at a fixed conversion price of KRW 5,660 from September 12, 2026 to August 12, 2028. Reported Earnings • May 19
First quarter 2025 earnings released: ₩478 loss per share (vs ₩64.00 loss in 1Q 2024) First quarter 2025 results: ₩478 loss per share (further deteriorated from ₩64.00 loss in 1Q 2024). Net loss: ₩7.29b (loss widened ₩6.32b from 1Q 2024). Revenue is forecast to grow 111% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Healthcare Services industry in Asia. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings. Announcement • Mar 08
SyntekaBio, Inc., Annual General Meeting, Mar 28, 2025 SyntekaBio, Inc., Annual General Meeting, Mar 28, 2025, at 11:00 Tokyo Standard Time. Location: seminar room, 18, gukjegwahak 17-ro, yuseong-gu, daejeon South Korea New Risk • Dec 09
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩18b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 2.9% per year over the past 5 years. Revenue is less than US$1m (₩122m revenue, or US$85k). Minor Risk Market cap is less than US$100m (₩77.5b market cap, or US$54.0m). New Risk • Dec 02
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩18b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩18b free cash flow). Earnings have declined by 2.9% per year over the past 5 years. Revenue is less than US$1m (₩122m revenue, or US$87k). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩104.1b market cap, or US$74.1m). New Risk • Aug 31
New minor risk - Financial position The company has less than a year of cash runway based on its current free cash flow. Free cash flow: -₩23b This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩124m revenue, or US$93k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩23b). Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₩99.3b market cap, or US$74.4m). New Risk • May 30
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩137.0b (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 49% over the past year. Revenue is less than US$1m (₩123m revenue, or US$90k). Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (₩137.0b market cap, or US$99.5m). Announcement • May 24
Syntekabio to Showcase Advanced AI Drug Discovery Technologies at BIO International Convention 2024 Syntekabio announced its participation at the BIO International Convention 2024, where the company will highlight its innovative AI-driven drug discovery technologies. The convention will be held June 3-6, 2024, at the San Diego Convention Center, San Diego, CA. At the convention, Syntekabio will showcase DeepMatcherTM, its versatile, disease-agnostic platform that generates small molecule hits, leads, and drug candidates against multiple targets. Additionally, the company will highlight its in-silico biologics platforms, Neo-ARSTM and Ab-ARSTM, which enable personalized or universal neoantigen cancer vaccine and novel antibody drug prediction, respectively. These cutting-edge solutions address complex challenges in drug discovery, equipping researchers with powerful tools to develop novel and effective therapeutics. Announcement • May 08
Syntekabio Announces to Showcase Biologics Discovery Platform At PEGS Boston Syntekabio announced its participation at the 20th Annual PEGS Boston - The Essential Protein & Antibody Engineering Summit, where the company will highlight its novel biologics platform. The event is being held May 13-17, 2024 at the Omni Hotel at the Seaport, Boston, MA. Following the recent launch of its AI-driven drug discovery services in the US and Europe and the rollout of STB LaunchPad, Syntekabio's versatile technology platform for small molecule drug candidate generation, the company is excited to showcase its in-silico biologics discovery capabilities with Neo-ARS, its cutting-edge AI platform for personalized or universal neoantigen prediction, so-called tumor-specific cancer vaccines, as well as Ab-ARS for the prediction of novel complementarity-determining regions (CDRs) of antibody heavy chains. Neo-ARS was developed in partnership with Chungnam National University Hospital, Korea and already has shown promising results in identifying and evaluating cancer neoantigens for acute myeloid leukemia (AML), demonstrating its potential in personalized immunotherapy. In a strategic move to bring these advancements to patients, Syntekabio has partnered with Metaclipse Therapeutics, a US biotechnology company developing immunotherapies for cancer and vaccines for infectious disease. The companies have signed a memorandum of understanding to initiate a joint research project, which will utilize Neo-ARS to identify highly immunogenic neoantigens, critical for the development of effective cancer vaccines and personalized immunotherapies. Ab-ARS and Neo-ARS facilitate rapid antibody prediction and optimization by leveraging a vast hydrogen-bonded peptide-peptide interaction database, as well as AI-driven 3D modeling. This is complemented by phage display experiments. Antibody heavy chains predicted by this technology, as well as personalized neoantigen-driven immunogenicity, can be used upstream to innovative therapeutic antibody designs, including bispecific T-cell engagers, multi-specific antibodies, and nanobodies. Announcement • Apr 27
SyntekaBio, Inc. announced that it has received KRW 10 billion in funding from Korea Investment Partners Co. Ltd. On April 26, 2024, SyntekaBio, Inc. closed the transaction. Announcement • Apr 11
Syntekabio to Showcase Innovative AI Drug Discovery Technologies at Bio-IT World Syntekabio announced its participation at the upcoming Bio-IT World Conference & Expo. The company has recently launched its drug discovery services in the US and Europe and is introducing STB LaunchPad, Syntekabio's proprietary disease-agnostic technology platform that is able to generate hits, leads, and drug candidates against multiple targets. Viable leads are further optimized and experimentally validated in cooperation with its global network of contract research organizations (CROs), and an IND-enabling package then is delivered to the client. AI technologies can supercharge data analysis and facilitate rapid drug discovery, but they still require significant case-by-case tailoring and experimental validation. Dr. Kruzel will present Syntekabio's disease-agnostic approach to AI-driven drug discovery that yields viable drug candidates. Bringing together biology, AI, and cloud technologies, Syntekabio is working in a factory-like mode, continuously generating novel and viable drug candidates for a wide range of diseases. The goal: don't make the patients wait. New Risk • Apr 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 49% over the past year. Revenue is less than US$1m (₩123m revenue, or US$91k). Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). Announcement • Jul 29
SyntekaBio, Inc. announced that it has received KRW 10 billion in funding On July 28, 2023, SyntekaBio, Inc. closed the transaction. New Risk • Jul 12
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 47% over the past year. Revenue is less than US$1m (₩169m revenue, or US$131k). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (6.0% increase in shares outstanding). New Risk • Jun 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 47% over the past year. Revenue is less than US$1m (₩169m revenue, or US$129k). Minor Risk Share price has been volatile over the past 3 months (9.0% average weekly change). Announcement • Jun 04
Syntekabio Announces the Launch of its Cost-Effective AI-Based Total Solution Service for Finding New Drug Candidates Syntekabio announced the launch of its cost-effective AI-based total solution service for finding new drug candidates. STB CLOUD works as a comprehensive one-stop solution built on Syntekabio's own proprietary AI platform DeepMatcher®, powered by supercomputing technology. The total solution supports auto-hit-discovery, auto-lead-generation, auto-ADMET/PK (at task), and PGx biomarker for drug labeling. Using deep-learning analysis and automatic molecular dynamics (MD) simulation technology for target proteins, the solution generates pre-stage, pre-clinical candidates within two years, including the completion of animal testing. This process drastically shortens the period before pre-clinical trials to two years from what averages to be up to seven years in traditional drug development. Generally, it takes three to four years for candidate discovery and screening, one to three years for optimization, and the same length for non-clinical and toxicity tests. Adding five to six years for clinical trials and a couple more years for commercialization, the time it takes for full drug development from discovery can last many years causing the development price tag to go up while losing potential return on investment. Furthermore, Traditional new drug development can cost more than 10 million dollars until pre-clinical trials. Syntekabio’s STB CLOUD not only saves time but achieves substantial cost savings as it is set at only two million dollars for the entire cycle of drug development. Currently, Syntekabio is conducting two studies in the area of auto-ADMET/PK (at task). The first is about toxicity and metabolism caused by protein binding, which is modeled based on the 3D convolutional neural network (3D-CNN). The second study is on passive delivery and permeability due to the physical and chemical properties of the compound itself, which will be implemented with pre-trained generative transformers models, such as GPT-2, using large-scale compound databases. Syntekabio’s new drug discovery solutions will be unveiled at the 2023 BIO International Convention in Boston, June 5-8, 2023 at booth #2785. Is New 90 Day High Low • Feb 15
New 90-day low: ₩18,000 The company is down 18% from its price of ₩21,850 on 17 November 2020. The South Korean market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is down 3.0% over the same period. Is New 90 Day High Low • Jan 29
New 90-day low: ₩19,150 The company is down 29% from its price of ₩27,000 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is down 1.0% over the same period. Is New 90 Day High Low • Dec 04
New 90-day low: ₩20,600 The company is down 16% from its price of ₩24,500 on 04 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is down 6.0% over the same period. Is New 90 Day High Low • Sep 24
New 90-day high: ₩31,600 The company is up 123% from its price of ₩14,200 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 7.0% over the same period. 